Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$27,000.00

Developing a “one-two punch” treatment paradigm for glioblastoma

EF 2024-25

Résumé
Glioblastoma (GBM) is the most common and deadly form of adult brain cancer. Despite surgery and chemoradiation therapies, GBM remains lethal within 15-18 months of diagnosis. A critical barrier to treating GBM is the ability of glioma stem cells (GSCs) to invade healthy brain tissue, evade therapies, and repopulate the tumour. Current treatments target rapidly dividing cells instead of invading GSCs, overlooking the primary driver of tumour spread and recurrence. Thus, targeting GSC invasion, rather than proliferation, offers a novel approach to addressing this critical gap in GBM therapy.Our previous research has shown that inhibiting MAP4K4, a protein critical for GSC migration, significantly reduces their invasive capacity and induces a stress response in these cells. While not inherently lethal, this stress response forms the basis for a novel one-two punch paradigm. The first punch involves immobilizing GSCs through inhibiting MAP4K4, making them susceptible to a subsequent second punch treatment that exploits the induced stress response and eliminates them entirely. This project aims to characterize the molecular changes triggered by MAP4K4 inhibition and identify second-punch treatments that capitalize on the vulnerabilities of immobilized GSCs. By addressing the invasive, rather than proliferative, properties of GBM, this research aims to overcome the limitations of current therapies. The remarkable ability of GBM to develop resistance to single-drug therapies further underscores the need for combinatorial approaches. The proposed one-two punch strategy has the potential to revolutionize GBM treatment by targeting the invasive biology of the disease, offering a novel therapeutic avenue to improve patient outcomes.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
529814
Name
Omoto Lauren C
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Developing a “one-two punch” treatment paradigm for glioblastoma
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cerebral Organoids; Glioblastoma; Glioma Stem Cells (Gsc); Invasion Assay; Proteomics; Targeted Therapy; Transcriptomics
Abstract
Glioblastoma (GBM) is the most common and deadly form of adult brain cancer. Despite surgery and chemoradiation therapies, GBM remains lethal within 15-18 months of diagnosis. A critical barrier to treating GBM is the ability of glioma stem cells (GSCs) to invade healthy brain tissue, evade therapies, and repopulate the tumour. Current treatments target rapidly dividing cells instead of invading GSCs, overlooking the primary driver of tumour spread and recurrence. Thus, targeting GSC invasion, rather than proliferation, offers a novel approach to addressing this critical gap in GBM therapy.Our previous research has shown that inhibiting MAP4K4, a protein critical for GSC migration, significantly reduces their invasive capacity and induces a stress response in these cells. While not inherently lethal, this stress response forms the basis for a novel one-two punch paradigm. The first punch involves immobilizing GSCs through inhibiting MAP4K4, making them susceptible to a subsequent second punch treatment that exploits the induced stress response and eliminates them entirely. This project aims to characterize the molecular changes triggered by MAP4K4 inhibition and identify second-punch treatments that capitalize on the vulnerabilities of immobilized GSCs. By addressing the invasive, rather than proliferative, properties of GBM, this research aims to overcome the limitations of current therapies. The remarkable ability of GBM to develop resistance to single-drug therapies further underscores the need for combinatorial approaches. The proposed one-two punch strategy has the potential to revolutionize GBM treatment by targeting the invasive biology of the disease, offering a novel therapeutic avenue to improve patient outcomes.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Omoto, Lauren C
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~